|
|
Phase I Study of Photodynamic Therapy Using HPPH in Patients With In Situ or Microinvasive Bronchogenic Non-Small Cell Carcinoma
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outcomes Outline Trial Contact Information Registry Information
Alternate Title
Photodynamic Therapy Using HPPH in Treating Patients With Stage 0 Non-Small Cell Lung Cancer
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase I
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
RPCI-I-05903 I 05903, NCT00526461
|
|
|
Objectives Primary - To determine the maximally tolerated light dose (MTID) in patients with bronchogenic carcinoma in situ (CIS) or bronchogenic microinvasive carcinoma.
- To identify the systemic and normal tissue toxicity resulting from photodynamic therapy using HPPH in these patients.
Secondary - To study tumor response in these patients.
Entry Criteria Disease Characteristics:
- Biopsy confirmed carcinoma in situ (CIS) or microinvasive bronchogenic non-small cell lung carcinoma
- May have squamous cell carcinoma, adenocarcinoma, or large cell carcinoma histology
- Stage 0 (CIS or microinvasive) disease, meeting all of the following criteria:
- Lesion must be radiographically occult and not definable by conventional CT scan of the chest
- Lesion may or may not be invisible on white light bronchoscopy, but is definable and photographable on laser-induced fluorescence emission (LIFE) bronchoscopy
- Biopsy of the lesion must indicate no evidence of invasion beyond cartilage on histopathology, but may be invasive through the basement membrane (microinvasive carcinoma)
- No evidence of major pulmonary vessel encasement on CT scan of the chest
Prior/Concurrent Therapy:
- More than 4 weeks since prior and no concurrent chemotherapy or radiotherapy
- Prior therapy of any type (e.g., chemotherapy or radiotherapy) allowed for lung cancer
Patient Characteristics:
- Karnofsky performance status (PS) 50-100% OR ECOG PS 0-2
- Platelet count ≥ 100,000/mm3
- WBC ≥ 4,000/mm3
- Prothrombin time ≤ 1.5 times upper limit of normal (ULN)
- Total bilirubin ≤ 3.0 mg/dL
- Creatinine ≤ 3.0 mg/dL
- Alkaline phosphatase (hepatic) or SGOT ≤ 3 times ULN
- No porphyria or hypersensitivity to porphyrin or porphyrin-like compounds
- No severe chronic obstructive pulmonary disease, that in the opinion of the investigator, would preclude multiple bronchoscopies or partial central airway obstruction from mucous/debris formation
- Patients with underlying lung disease must be judged (by the principal investigator) able to withstand mucous or debris formation at the site of treatment
- No contraindications for bronchoscopy
- Not pregnant
- Negative pregnancy test
- Fertile patients must use effective contraception
Expected Enrollment 24Outcomes Primary Outcome(s)Toxicity as measured by NCI CTC v2.0
Secondary Outcome(s)Tumor response
Outline Patients receive HPPH IV over 1 hour on day 1. Approximately 2 days later, patients undergo photodynamic therapy (PDT) using laser light passed through the biopsy channel of an endoscope. Patients undergo endoscopic debridement on day 5. If viable tumor is found outside of the initial treatment area, patients may receive another dose of laser light without additional HPPH at that time. After completion of study treatment, patients are followed at 4-6 weeks, 6 months, and periodically thereafter.
Trial Contact Information
Trial Lead Organizations Roswell Park Cancer Institute | | | Todd Demmy, MD, Principal investigator | | Ph: 716-845-5873; 800-685-6825 |
| | Trial Sites
|
|
|
|
U.S.A. |
|
New York |
|
|
Buffalo |
|
| | | | | | | | Roswell Park Cancer Institute |
| | Clinical Trials Office - Roswell Park Cancer Institute | |
|
Registry Information | | Official Title | | A Phase I Study Light Dose for Photodynamic Therapy (PDT) Using 2-[1-hexyloxyethyl]-2 devinyl Pyropheophorbide-a (HPPH) for Treatment of Non-Small Cell Carcinoma in Situ or Non-Small Cell Microinvasive Bronchogenic Carcinoma: A Dose Ranging Study | | Trial Start Date | | 2004-02-25 | | Trial Completion Date | | 2012-07-03 (estimated) | | Registered in ClinicalTrials.gov | | NCT00526461 | | Date Submitted to PDQ | | 2007-08-14 | | Information Last Verified | | 2008-04-20 | | NCI Grant/Contract Number | | CA16056 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|